Le Lézard
Classified in: Health, Business
Subject: CXP

Anpac Bio Launches Major U.S. Expansion, Starting 2nd U.S. Clinical Lab in Philadelphia


SAN JOSE, Calif., Oct. 14, 2019 /PRNewswire/ -- After winning a major award from the U.S. Department of Commerce as "Minority Health Products and Services Firm of the Year," and obtaining CLIA certification for its clinical laboratory in San Jose earlier this year, Anpac Bio-Medical Science Co., Ltd. ("Anpac Bio") today announced a major expansion in the U.S. by selecting Philadelphia as its second clinical laboratory site and new U.S. corporate headquarters.

CEO Dr. Chris Yu inspects Anpac Bio's proprietary "Cancer Differentiation Analysis" (CDA) liquid biopsy technology that consistently detects 26+ cancers (at 75%-90% sensitivity/specificity rates), usually at its earliest stages. Fully-commercialized with 200 patents filed worldwide, Anpac Bio and medical partners are celebrating #WorldCancerDay by surpassing a global milestone: processing 60,000+ independently-corroborated CDA tests for early cancer screening and monitoring treatment/recurrence.

Of this expansion, CEO Dr. Chris Yu remarked, "With our leading-edge technology extensively validated by 40,000 blood samples from our research studies and 100,000 blood samples from our cancer risk assessment using CDA-based tests in China, we are now fully committed to R&D and market penetration in the U.S. By placing our second clinical laboratory in Philadelphia, we can work with our hospital principal investigators and partners in the East Coast much more closely and effectively."

Anpac Bio's new U.S. corporate headquarters and laboratory will be centrally located in the Mid-Atlantic region and easily accessible to key markets. The 7,000 square foot office and lab space will be located in the Spring House Innovation Park which also houses the Jefferson Institute for Bioprocessing. Philadelphia was recently named the latest of the Big4Bio regions for its innovation in the life sciences sector and home to more than 800 life sciences companies and 15 major health systems.

"We are very excited to be moving forward with our U.S. corporate headquarters and laboratory in Pennsylvania. The state has a mature life sciences ecosystem and a supportive start-up environment that will allow our U.S. business to lay the foundation for future success," stated Shaun Gong, Anpac's U.S. President.

Anpac Bio is a leading biotechnology company focused on early cancer screening and detection. With multiple certified clinical laboratories in China, Anpac Bio markets a suite of cancer screening and detection tests, including CDA, bio-chemistry, immunology, and genomics tests. In a recent market research report by Frost & Sullivan, Anpac Bio ranked second worldwide among companies offering next-generation early cancer screening and detection technologies, based on approximately 35,000 clinical samples as at June 30, 2019. These clinical samples demonstrated that Anpac Bio's CDA technology could detect the risk of over 20 different cancer types with high sensitivity and specificity rates.

For further information visit: AnpacBio.com

International life sciences leader Anpac Bio-Medical Science Company has developed breakthrough, proprietary, "Cancer Differentiation Analysis" liquid biopsy technology that effectively reinvents cancer screening and early detection. Anpac Bio's proprietary CDA medical devices analyze simple, standard, non-invasive "Blood Biopsies" - resulting in measurably greater early cancer detection sensitivity and specificity, with no harmful side effects in patients. The proven results of 120,000 cases to date demonstrate CDA's research validity achieving an average sensitivity and specificity rate range of 75%-90% for 28+ different types of cancer -- often identifying the type and location of threatening, diseased cancer cells before they form into tumors. Fully-commercialized and the only company earning liquid biopsy revenue globally, Anpac Bio has filed 250+ CDA-related Patents; 101+ issued to date worldwide. For more information: AnpacBio.com. (PRNewsFoto/Anpac Bio-Medical Science Co.)

SOURCE Anpac Bio-Medical Science Co., Ltd.


These press releases may also interest you

at 10:15
Today, Investopedia announced the winners of its 2024 Best Online Broker Awards, featuring 14 categories highlighting winners whose products and services helped investors navigate rising but volatile markets, a crypto resurgence, and new assets like...

at 10:12
NerdsToGo®, a leading information technology (IT) solutions and technology repair services franchise for both business and home, announced today plans for its strategic expansion throughout the greater Chicago area with 20 new territories available...

at 10:10
The group division of Ameritas proudly announces its 17th consecutive certification as a BenchmarkPortal Center of Excellence, solidifying its position as a leader in customer service and support excellence. This prestigious recognition for 2023...

at 10:00
Frost & Sullivan recently researched the customer experience outsourcing services industry and, based on its findings, recognizes AeC with the 2023 Company of the Year Award. AeC is connecting technology with outstanding customer service to increase...

at 10:00
Seniors Helping Seniors® in-home care services, a franchisor with over 125 franchise partners and more than 200 territories nationwide, has grown rapidly in recent years by building a workforce of talented caregivers who create meaningful...

at 10:00
PKF Clear Thinking, the award-winning business advisory firm and subsidiary of PKF O'Connor Davies, one of the nation's largest accounting, tax and advisory practices, is proud to announce that it has been awarded the "Section 363 Sale of the Year...



News published on and distributed by: